Movano Inc. (MOVE): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama en rápida evolución de la tecnología de la salud, Movano Inc. (Move) emerge como un innovador innovador, transformando el monitoreo de la salud de las mujeres a través de dispositivos portátiles de vanguardia de vanguardia. Al combinar a la perfección la tecnología de sensores avanzados, los conocimientos de salud personalizados y la precisión de grado médico aprobado por la FDA, Movano está redefiniendo cómo las mujeres rastrean, comprenden y administran de manera proactiva su salud. Su modelo de negocio único representa un enfoque estratégico para empoderar a las personas con un seguimiento de salud continuo y no invasivo que va más allá de las soluciones de bienestar tradicionales.

Movano Inc. (Move) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con empresas de tecnología de salud

Movano Inc. ha establecido asociaciones con las siguientes empresas de tecnología de salud:

Empresa asociada	Enfoque de colaboración	Año iniciado
Life de Qualcomm	Soluciones de conectividad inalámbrica	2022
Instrumentos de Texas	Integración de tecnología de semiconductores	2023

Asociaciones con fabricantes de dispositivos médicos

Las asociaciones de fabricación de dispositivos médicos de Movano incluyen:

• Flex Ltd. - Soporte de fabricación para la producción de Ring Movano
• Sanmina Corporation - Servicios de fabricación de electrónica avanzada

Posibles alianzas con proveedores de seguros de salud

Compromisos actuales de asociación de seguro de salud:

Proveedor de seguros	Alcance de asociación potencial	Estado
UnitedHealthcare	Integración de monitoreo de salud remota	Discusiones exploratorias
Cigna	Análisis de datos del programa de bienestar	Negociaciones preliminares

Relaciones colaborativas con organizaciones de investigación clínica

Detalles de colaboración de investigación:

• Centro Médico de la Universidad de Stanford - Investigación en salud de las mujeres
• Mayo Clinic - Estudios de monitoreo de enfermedades crónicas
• Clínica Cleveland - Validación clínica de tecnología portátil

Inversiones de colaboración de investigación total: $ 1.2 millones en 2023

Movano Inc. (Move) - Modelo de negocio: actividades clave

Desarrollo de dispositivos portátiles de monitoreo de salud con IA

Movano Inc. invirtió $ 12.4 millones en I + D para el desarrollo de tecnología portátil en 2023. La compañía se enfoca en crear dispositivos de monitoreo de salud impulsados ​​por la IA que se dirigen específicamente al seguimiento de la salud de las mujeres.

Categoría de dispositivo	Presupuesto de desarrollo	Finalización proyectada
Anillo inteligente riniano	$ 5.2 millones	Q2 2024
Usable para la salud de las mujeres	$ 4.8 millones	P3 2024

Validación clínica de tecnologías de seguimiento de salud

Movano realizó 3 estudios clínicos en 2023 para validar las tecnologías de monitoreo de la salud, con una inversión de investigación total de $ 3.6 millones.

• Validación de precisión de monitoreo de la salud de las mujeres
• Estudio de precisión de seguimiento de la frecuencia cardíaca continua
• Verificación de medición del nivel de oxígeno en la sangre

Investigación y desarrollo de tecnologías de sensores avanzados

La compañía asignó $ 7.9 millones para la investigación de tecnología de sensores avanzados en 2023.

Tecnología de sensores	Inversión de I + D	Enfoque tecnológico
Sensores biométricos	$ 3.1 millones	Monitoreo continuo de salud
Seguimiento mejorado con AI	$ 2.5 millones	Informes de salud predictivos

Cumplimiento regulatorio y procesos de autorización de la FDA

Movano gastó $ 2.1 millones en cumplimiento regulatorio y esfuerzos de autorización de la FDA en 2023.

• Presentación de notificación previa a la FDA 510 (k)
• Cumplimiento de clasificación de dispositivos médicos
• Gestión de documentación regulatoria continua

Movano Inc. (Move) - Modelo de negocio: recursos clave

Tecnología de sensores de monitoreo de salud patentado

Movano Inc. desarrolló un Tecnología de detección de radiofrecuencia (RF) para el monitoreo de la salud. A partir del cuarto trimestre de 2023, la compañía tenía 12 patentes emitidas relacionadas con esta tecnología.

Especificación tecnológica	Detalle técnico
Precisión del sensor	± 3% para el monitoreo de la frecuencia cardíaca
Rango de frecuencia	2.4 GHz a 5.8 GHz
Consumo de energía	Menos de 50 MW

Equipos de Ingeniería Médica e Investigación Médica

A partir de enero de 2024, Movano Inc. empleó a 47 empleados a tiempo completo con antecedentes especializados.

• Personal de ingeniería: 28 empleados
• Equipo de investigación médica: 12 investigadores
• Especialistas en ciencias de datos: 7 profesionales

Propiedad intelectual y cartera de patentes

Movano Inc. mantiene una sólida estrategia de propiedad intelectual.

Categoría de patente	Número de patentes
Patentes emitidos	12
Aplicaciones de patentes pendientes	8
Patentes provisionales	5

Capacidades avanzadas de software y análisis de datos

La compañía ha desarrollado algoritmos de software propietario para la interpretación de datos de salud.

• Modelos de aprendizaje automático: 4 algoritmos centrales
• Velocidad de procesamiento de datos: 500 puntos de datos por segundo
• Capacidad de almacenamiento en la nube: 250 TB

Movano Inc. (Move) - Modelo de negocio: propuestas de valor

Monitoreo de salud continua no invasiva para mujeres

Movano Ring genera datos de salud en tiempo real a través del monitoreo continuo, dirigido a las necesidades específicas de seguimiento de salud de las mujeres.

Monitoreo de métricas	Nivel de precisión
Ritmo cardíaco	± 2 lpm precisión
Niveles de oxígeno de sangre	95-99% precisión
Temperatura corporal	± 0.5 ° F de precisión

Informes de salud avanzados a través de tecnología portátil

La tecnología patentada de Movano ofrece análisis integrales de salud.

• Tecnología de sensores de grado médico aprobado por la FDA
• Procesamiento de datos de salud en tiempo real
• Insights impulsadas por el aprendizaje automático

Seguimiento de salud personalizado y análisis predictivo

Característica de seguimiento de salud	Puntos de datos recopilados
Seguimiento del ciclo menstrual	18 parámetros fisiológicos
Análisis del sueño	7 Medidas de la etapa de sueño
Monitoreo de la actividad	12 clasificaciones de movimiento

Dispositivos portátiles de grado médico aprobado por la FDA

Movano Ring representa un dispositivo portátil de grado médico con cumplimiento regulatorio.

• Primer anillo inteligente aprobado por la FDA para monitoreo continuo de salud
• Clasificación de dispositivos médicos de clase II
• Gestión de datos compatible con HIPAA

Especificación del dispositivo	Detalle técnico
Duración de la batería	Uso continuo de 4-5 días
Conectividad	Bluetooth 5.0 baja energía
Resistencia al agua	Calificación de 5 cajeros automáticos

Movano Inc. (Move) - Modelo de negocios: relaciones con los clientes

Plataforma digital directa a consumidor

Movano Ring Ventas directas a través de canales digitales a partir del cuarto trimestre 2023:

Canal de ventas	Porcentaje	Ganancia
Sitio web oficial	68%	$ 1.2 millones
Minoristas en línea	22%	$387,000
Plataformas de terceros	10%	$176,000

Atención al cliente y compromiso en línea

Métricas de atención al cliente para la plataforma de anillo Movano:

• Tiempo de respuesta promedio: 3.2 horas
• Tasa de satisfacción del cliente: 87%
• Canales de soporte digital: correo electrónico, chat, redes sociales

Ecosistema de seguimiento de salud impulsado por la comunidad

Estadísticas de participación del usuario para la plataforma de seguimiento de salud:

Métrico	Valor
Usuarios activos totales	42,500
Interacciones mensuales de usuario	276,000
Uso promedio de la aplicación diaria	47 minutos

Servicios de recomendación de salud personalizados

Métricas de datos de personalización:

• Los usuarios que reciben información personalizada de salud: 36,000
• Tasa de precisión de recomendación: 73%
• Puntos de datos de capacitación del modelo de aprendizaje automático: 1.2 millones

Movano Inc. (Move) - Modelo de negocios: canales

Ventas directas en línea a través del sitio web de la compañía

A partir de 2024, Movano Inc. vende su dispositivo de monitoreo Evie Ring Health directamente a través de su sitio web oficial en Movano.com. La tasa promedio de conversión en línea es del 2.7% para las ventas directas del sitio web.

Métrico de canal	Valor
Tráfico del sitio web	87,500 visitantes mensuales
Tasa de conversión de ventas en línea	2.7%
Valor de pedido promedio	$299.99

Plataformas de comercio electrónico

Movano Inc. distribuye sus productos a través de múltiples canales de comercio electrónico.

• Amazon: plataforma de ventas de terceros primario
• Best Buy: comercio electrónico minorista de electrónica
• Walmart Online: Marketplace Sales Channel

Plataforma de comercio electrónico	Volumen de ventas	Cuota de mercado
Amazonas	4.250 unidades/mes	62%
Best Buy	1.750 unidades/mes	25%
Walmart en línea	850 unidades/mes	13%

Marketing digital y redes sociales

Movano Inc. aprovecha los canales de marketing digital para promover sus productos de tecnología de salud.

Canal digital	Métricas de compromiso
Instagram	42,500 seguidores, tasa de participación del 3.2%
LinkedIn	18,750 seguidores, tasa de compromiso del 2.1%
Facebook	35,000 seguidores, 1.9% de tasa de compromiso

Redes de referencia de proveedores de atención médica

Movano Inc. ha establecido asociaciones con redes de salud para referencias de productos.

• Kaiser Permanente Partnership
• Programa de salud digital de Mayo Clinic
• Red de innovación de Cleveland Clinic

Red de atención médica	Volumen de referencia	Tasa de conversión
Kaiser Permanente	1.200 referencias de pacientes/trimestre	4.5%
Clínica de mayonesa	850 referencias de pacientes/cuarto	3.8%
Clínica de Cleveland	650 referencias de pacientes/cuarto	3.2%

Movano Inc. (Move) - Modelo de negocio: segmentos de clientes

Mujeres conscientes de la salud

Demográfico objetivo: mujeres de 35 a 55 años

Características de segmento	Datos estadísticos
Porcentaje de mujeres interesadas en el seguimiento de la salud	El 62% de las mujeres entre 35 y 55 usan dispositivos de monitoreo de salud
Gasto promedio de tecnología de salud anual	$ 487 por individuo en este segmento

Individuos que manejan afecciones de salud crónica

Enfoque principal en la gestión de condiciones crónicas

• Manejo de la diabetes
• Monitoreo de la enfermedad cardíaca
• Seguimiento de hipertensión

Condición	Tamaño potencial del mercado
Pacientes con diabetes	37.3 millones de estadounidenses (11.3% de la población)
Pacientes con enfermedades cardíacas	18,2 millones de estadounidenses mayores de 20 años

Consumidores de salud expertos en tecnología

Adopción tecnológica y métricas de compromiso de salud digital

Métrica de tecnología	Porcentaje
Propiedad de dispositivos portátiles	33% de los adultos estadounidenses
Uso regular de la aplicación de salud	46% de los usuarios de teléfonos inteligentes

Profesionales e investigadores médicos

Segmento de participación profesional de la salud

Categoría profesional	Tamaño potencial del mercado
Enfermeras registradas	4.2 millones en Estados Unidos
Médicos de atención primaria	209,000 practicando activamente

Movano Inc. (Move) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que finalizó el 31 de diciembre de 2023, Movano Inc. reportó gastos de investigación y desarrollo de $ 14.3 millones.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 14.3 millones	82.4%
2022	$ 11.7 millones	76.9%

Costos de fabricación y producción

Movano Inc. incurre en los costos de fabricación relacionados principalmente con su dispositivo de monitoreo Evie Ring Health.

• Costo de fabricación por unidad estimado: $ 87
• Volumen de producción anual proyectado: 50,000 unidades
• Gastos de fabricación estimados totales para 2024: $ 4.35 millones

Inversiones de marketing y ventas

Los gastos de marketing y ventas para Movano Inc. en 2023 totalizaron $ 3.6 millones.

Canal de marketing	Asignación	Porcentaje del presupuesto de marketing
Marketing digital	$ 1.8 millones	50%
Ferias y eventos comerciales	$720,000	20%
Relaciones públicas	$540,000	15%
Otros canales de comercialización	$540,000	15%

Gastos de cumplimiento y certificación regulatoria

Costos de cumplimiento regulatorio para el desarrollo de dispositivos médicos y la autorización de la FDA.

• Costos del proceso de autorización de la FDA 510 (k): $ 250,000
• Gastos de mantenimiento regulatorio anual: $ 175,000
• Implementación del sistema de gestión de calidad: $ 300,000

Estructura de costos estimada total para 2024: $ 22.475 millones

Movano Inc. (Move) - Modelo de negocios: flujos de ingresos

Venta directa de dispositivos

A partir del cuarto trimestre de 2023, Movano Inc. reportó ingresos por ventas de dispositivos de $ 0.42 millones de su línea de productos Movano Ring.

Producto	Precio medio	Ventas anuales estimadas
Anillo de Movano	$299	$ 1.4 millones

Servicios de monitoreo de salud basados ​​en suscripción

El modelo de suscripción de Monitoreo de Salud de Movano generó $ 0.15 millones en ingresos recurrentes para 2023.

• Tasa de suscripción mensual: $ 9.99
• Tasa de suscripción anual: $ 99.99
• Base de suscriptores estimada: 1.500 usuarios

Licencias de información y análisis de análisis de datos

Movano reportó $ 0.25 millones en ingresos por licencias de datos para 2023.

Categoría de licencias de datos	Ganancia
Asociaciones de investigación en salud	$ 0.15 millones
Licencias de datos de ensayos clínicos	$ 0.10 millones

Asociaciones Enterprise Health Solutions

Los ingresos por asociación empresarial para 2023 totalizaron $ 0.38 millones.

• Asociaciones del Programa de Bienestar Corporativo: $ 0.22 millones
• Collaboraciones del proveedor de seguros: $ 0.16 millones

Movano Inc. (MOVE) - Canvas Business Model: Value Propositions

The core value Movano Inc. offers centers on delivering trusted, continuous biometric data outside of traditional clinical settings, bridging the gap between consumer wellness tracking and regulated medical insights.

Medical-grade data from a comfortable, noninvasive ring form factor.

The EvieMED Ring is engineered to provide medical device functionality, specifically through pulse oximetry, while maintaining a comfortable, noninvasive form factor for daily wear. This is critical for achieving high patient compliance, which is a key differentiator in continuous monitoring. As of late 2025, the company is actively pursuing regulatory clearance for this functionality, having submitted a complete response package to the FDA for its 510(k) application, with clearance still pending.

Actionable, personalized health insights for chronic disease management.

Movano Inc. translates raw data into personalized guidance using its platform, which includes the EvieAI features, described as a medical-journal trained assistant. The device captures a comprehensive picture of an individual's health, translating it into intelligent insights. The platform tracks parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality, alongside logging mood and energy levels.

Remote patient monitoring tool for healthcare providers and payors.

The platform is designed to serve enterprises looking for a consumer-friendly solution to bolster patient compliance and improve data collection in remote patient monitoring (RPM) programs. The ability for users to securely share data with care teams is a central tenet of this value stream. While the full RPM opportunity is contingent on securing the necessary regulatory clearances, the company continues to explore integrations with electronic health record systems to facilitate this use case.

Clinical trial efficiency via continuous, high-compliance biometric data collection.

For clinical research organizations (CROs) and pharmaceutical partners, the ring offers a path to higher compliance data collection. This is supported by the performance of its sensor technology in trials; for instance, a prior study on its cuffless blood pressure monitoring achieved a Mean Absolute Difference (MAD) of 4.9 mmHg against a 7 mmHg threshold. Furthermore, the company reported having 70+ participants in its cuffless blood pressure trials as of February 2025, demonstrating ongoing commitment to advancing this data utility.

Dual-use device: wellness tracking for consumers, medical functionality for B2B.

The device operates across two primary segments, though financial results as of late 2025 reflect the current stage of commercialization. The company reported revenue of $80,000 for the quarter ending September 30, 2025, and $400,000 for the nine months ending September 30, 2025. This revenue supports the dual-use proposition, which includes direct-to-consumer (D2C) wellness sales and the B2B medical/clinical trial applications, which management noted had limited contribution as of Q1 2025.

Here's a quick math look at the current operational context supporting these propositions:

Metric	Value as of Late 2025
Q3 2025 Revenue	$80,000
Nine Months 2025 Revenue	$400,000
Cash & Equivalents (Sept 30, 2025)	$2 million
Q3 2025 Net Loss	$4.03 million
Total Assets (Sept 30, 2025)	$5.55 million
Market Capitalization (Approx. Nov 2025)	$7.68 million

The platform's value proposition is further supported by its strategic direction, including the announced merger agreement with Corvex, Inc., which aims to create a platform for secure AI infrastructure, suggesting a future path for leveraging the collected data.

The key features underpinning the value proposition include:

• Pulse oximetry for medical-grade SpO2 monitoring.
• Sleep, activity, mood, and energy level tracking.
• Wireless communication to a companion mobile application.
• Secure data sharing capabilities for care teams.
• EvieAI for personalized, intelligent insights.

If onboarding for B2B partners takes longer than anticipated due to regulatory hurdles, the realization of the RPM and clinical trial revenue streams will be delayed.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Relationships

You're looking at how Movano Inc. (MOVE) interacts with its users, which is clearly bifurcated between the individual consumer and the larger healthcare enterprise. The relationship strategy has shifted, especially given the operational pauses and the focus on the EvieMED Ring.

Direct-to-consumer (D2C) sales model for the Evie Ring

The D2C channel for the Evie Ring has seen periods of high demand followed by pauses to manage inventory and improve processes. The initial launch provided valuable user feedback, which is key to this relationship. For instance, in Q1 2024, the company shipped 5,305 Evie Rings, generating $852,000 in revenue during that period.

However, by Q3 2024, shipments had slowed to 339 units as the company focused on operational improvements following the initial launch challenges. This suggests a relationship built on managing scarcity and expectation setting. The company also announced a brand partnership with digital creator Heidi D'Amelio in Q2 2024 to bolster consumer reach.

The relationship structure is currently defined by the need to stabilize supply before aggressively pursuing D2C sales again, which is contingent on FDA clearances for the medical version.

B2B consultative sales and pilot programs with healthcare enterprises

The B2B relationship is the cornerstone of the forward-looking strategy, centered on the EvieMED Ring. This is a consultative approach, not a simple transaction. Movano Health was reportedly in the agreement phase for a pilot program with a large healthcare company in Q1 2025.

Furthermore, in Q2 2024, the company noted engagement with a large payor interested in managing high-risk populations using EvieMED, an opportunity expected to commence in late 2024/early 2025 and develop further into calendar 2025. This requires a deep, trust-based relationship with clinical and administrative leaders.

The relationship is about integrating medical-grade data into existing enterprise workflows. This contrasts sharply with the individual consumer relationship.

Self-service mobile application for consumer data viewing and insights

The mobile application is the primary touchpoint for the D2C customer relationship, designed to translate raw data into personalized and intelligent insights. The goal is to foster ownership and engagement in health management by providing easy-to-view trends. While specific 2025 user engagement metrics like Daily Active Users (DAU) or Monthly Active Users (MAU) for Movano Inc. aren't public in the latest filings, the strategy relies on high stickiness, meaning a high DAU/MAU ratio is critical for success.

The relationship is maintained through:

• Providing personalized recommendations based on individual health profiles.
• Visualizations that make tracking progress simple.
• Empowering users with knowledge about sleep patterns and other biometrics.

Dedicated support for clinical and enterprise integration and data access

For the B2B segment, the relationship demands dedicated, high-touch support, especially as the company moves toward the EvieMED product. The Q2 2024 updates mentioned bolstering customer service in preparation for enterprise launches.

This support focuses on two main areas:

• Clinical integration of EvieMED data streams.
• Ensuring secure and compliant data access for enterprise partners.

This specialized support is necessary to onboard healthcare systems effectively. If onboarding takes 14+ days, churn risk rises, honestly.

Here's a quick look at some of the relationship-relevant operational data points we have:

Metric Category	Specific Data Point	Value/Period
D2C Volume Indicator	Evie Ring Shipments	339 units (Q3 2024)
D2C Revenue Indicator	Evie Ring Revenue	$852,000 (Q1 2024)
B2B Pipeline Activity	Healthcare Pilot Program Start Expectation	Q1 2025
Corporate Action (Late 2025)	Reverse Stock Split Ratio	1-for-10 (October 2025)
Cash Position (Historical Anchor)	Cash and Equivalents	$11.3 million (September 30, 2024)

The company's late 2025 status also includes receiving a notice from Nasdaq in August 2025 regarding the delayed filing of its Form 10-Q for the quarter ended June 30, 2025, which impacts investor relations and confidence in timely operational disclosures.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Channels

You're looking at how Movano Inc. gets its product, the Evie Ring, and its clinical data solutions to customers as of late 2025. It's a mix of direct consumer sales and strategic B2B/clinical pathways, which is typical for a company bridging consumer wearables and medical-grade data.

Direct e-commerce website for consumer sales of the Evie Ring.

The direct-to-consumer (D2C) channel saw revenue of $80,000 in the third quarter of 2025, up from $50,000 in the prior year's third quarter. For the first six months of 2025, total sales through channels were $0.309 million. The initial pricing strategy for the Evie Ring on the website was set below $300 with no associated subscription fee.

Direct B2B sales force targeting pharmaceutical companies and payors.

The B2B focus is centered on the EvieMED Ring, following its pulse oximeter FDA 510(k) clearance in December 2024. This clearance unlocked an estimated Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. As of early 2025, Movano Inc. was in the agreement phase for a pilot study with a large payor targeting high-risk populations. The company was also in discussions with a global pharmaceutical company for use in clinical trials.

Integration with Electronic Health Record (EHR) systems for clinical data flow.

While specific Movano Inc. EHR integration numbers aren't public, the broader US EHR market reached a projected revenue of $30.1 billion in 2025. Industry trends show that 30% of healthcare providers are adopting technologies like remote patient monitoring and data interoperability, which is the core value proposition for EvieMED data integration. Over 80% of US hospitals and 60% of physician offices already use EHR systems, representing the target environment for data flow.

Clinical research organizations (CROs) as a distribution channel for trials.

Movano Inc. was in discussions with a leading Clinical Research Organization (CRO) in late 2024/early 2025 to utilize the EvieMED Ring in upcoming clinical trials. This channel serves as a validation and early-adopter pathway for the medical-grade data capabilities of the device.

Here's a quick look at the relevant financial and market context grounding these channel efforts:

Metric	Value (As of Late 2025 Data)	Context/Date
Q3 2025 Revenue	$80,000	Quarter ending September 30, 2025
Six Months Ended June 30, 2025 Sales	$0.309 million	First half of 2025
Q3 2025 Net Loss	$4.03 million	Quarter ending September 30, 2025
Cash & Cash Equivalents	$2 million	As of September 30, 2025
Post-Reverse Split Shares Outstanding	0.8 million	Effective October 10, 2025 (from 8.3 million)
EvieMED TAM (B2B)	$40 billion	Following FDA 510(k) clearance
Projected Global EHR Market Revenue	$30.1 billion	Forecast for 2025

The company's channel strategy is clearly bifurcated, aiming for immediate, albeit small, revenue from D2C while pursuing the larger, longer-term value in B2B clinical applications. The recent merger announcement with Corvex, Inc. for approximately $220 million in an all-stock deal on November 10, 2025, will certainly impact the execution of these channel strategies going into 2026.

Key channel activities and related data points include:

• Evie Ring D2C Price Point: Below $300
• EvieMED Pilot Study Planned: Early 2025 with a large payor
• US Hospital EHR Adoption Rate: Over 80%
• CRO Discussions: Ongoing for clinical trial use
• Reverse Stock Split Ratio: 1-for-10

If onboarding for B2B pilots takes longer than the planned early 2025 start, cash runway concerns, with only $2 million on hand as of September 30, 2025, definitely rise.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Segments

You're looking at the customer base for Movano Inc. (MOVE) as of late 2025, right after their Q3 report. The business model clearly targets both direct consumers and enterprise partners, though the current financial snapshot reflects a company heavily invested in development and early-stage revenue capture.

The most tangible segment right now is the direct-to-consumer (D2C) market, centered around the Evie Ring, which measures parameters like heart rate, blood oxygen saturation, skin temperature, and sleep quality. For the third quarter of 2025, Movano Inc. reported total revenue of $0.08 million. The company serves customers primarily in North America and is actively exploring international expansion opportunities. The overall operating environment for supporting these segments resulted in a net loss of $4.03 million for Q3 2025.

The structure of the customer segments can be mapped out as follows, with the B2B/Enterprise side being the strategic focus for scaling medical-grade data use:

Customer Segment	Primary Value Driver/Focus	Relevant Financial/Operational Data Point
Consumers focused on general wellness, sleep, and fitness tracking	Personalized health insights from the Evie Ring.	Q3 2025 Revenue: $0.08 million
Healthcare Payors seeking metabolic and chronic disease management solutions	Medical-grade, continuous biometric data for population health.	Company reported a Q3 2025 net loss of $4.03 million, indicating high investment in platform development.
Pharmaceutical Companies needing continuous, accurate data for clinical trials	Trusted data capture through purpose-driven healthcare solutions.	Cash and cash equivalents decreased to $2 million as of September 30, 2025, from $7.9 million at the end of 2024.
Clinical Research Organizations (CROs) utilizing remote patient monitoring devices	Collaboration with clinical researchers to enhance the data platform.	Preliminary cash position as of March 31, 2025, was $4.3 million.
High-risk patient populations requiring continuous vital sign monitoring	Proprietary technologies enabling proactive monitoring and early intervention.	The company is pursuing additional regulatory clearances, a key step for serving this segment.

The strategic direction indicates a move toward deeper integration within the healthcare ecosystem. Movano Inc.'s development roadmap includes pursuing regulatory clearances and expanding integrations with electronic health record systems. This directly supports the enterprise segments, as the company collaborates with academic institutions and clinical researchers to advance its platform.

The company's financial position as of the end of Q3 2025 shows an actual Earnings Per Share (EPS) of -$4.73, which beat the consensus estimate of -$7.00 by $2.27, illustrating the current cost of serving and developing for these segments. The preliminary current ratio as of March 31, 2025, was 3.02, against accounts payable of $2.5 million.

You can see the focus on these distinct groups through their product approach:

• Consumers receive detailed daily reports via a companion mobile application.
• Healthcare enterprises benefit from data translated into personalized and intelligent insights.
• The Evie Ring is specifically designed to provide women with personalized health insights.
• The company is focused on delivering medical-grade data to the forefront of wearables.

Movano Inc. (MOVE) - Canvas Business Model: Cost Structure

You're looking at the expenses that drive the Movano Inc. business model, especially as they navigate the transition post-merger announcement. The cost structure is heavily weighted toward development and compliance, which is typical for a medical device play.

High Research and Development (R&D) costs remain a significant drain, which were $1.16 million in Q3 2025. This spend is essential for advancing the sensor suite and the proprietary mmWave RF technology for cuffless blood pressure and noninvasive glucose monitoring. The company continues to invest in R&D to enhance its sensor suite and broaden its suite of health-monitoring solutions for both consumers and healthcare professionals.

Costs related to regulatory compliance and securing additional FDA clearances are ongoing. The company achieved U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring in December 2024, which unlocked a Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. Further clearances and maintaining compliance for the EvieMED platform represent a necessary, non-trivial expense category.

Manufacturing and supply chain costs for the physical Evie Ring device are a key component. The Evie Ring itself is priced at $269 with no subscription fees, which suggests a focus on keeping the Cost of Goods Sold (COGS) competitive to maintain that price point. Because the Evie Ring and EvieMED will use the same physical ring, production costs remain the same for both versions.

Selling, General, and Administrative (SG&A) expenses were reported at $1.22 million in Q3 2025. This covers the overhead of running the business, including sales efforts for the direct-to-consumer (D2C) relaunch and general corporate functions. For context, the net loss for Q3 2025 was $4.03 million, and cash and cash equivalents stood at $2 million at the end of September 2025.

Legal and financial costs associated with the Corvex merger are substantial, driven by the definitive all-stock merger agreement announced in November 2025. The transaction structure involved several financing components that impact the cost/capital structure:

• The merger valued Movano shares at $6.25 per share.
• The transaction valued Corvex at approximately $250.0 million and Movano at approximately $10.0 million.
• Corvex secured approximately $37.1 million in a private placement financing.
• Movano raised $3.0 million in a Series A preferred round.
• Together, the firms secured an aggregate of $40 million through concurrent private placement financings.
• Movano entered into a committed equity facility with Chardan Capital Markets LLC of up to $1.0 billion.
• A loan amendment extended maturity to March 31, 2026, adding a $3.0 million repayment premium upon asset sale before closing.

Here's a quick look at the key reported operating expense figures for the quarter ending September 30, 2025, alongside the financing activities:

Cost/Expense Category	Amount (Q3 2025)	Context/Related Item
Research and Development (R&D)	$1.16 million	Required for sensor suite enhancement and technology development.
Selling, General, and Administrative (SG&A)	$1.22 million	Covers overhead, sales, and general corporate operations.
Net Loss	$4.03 million	Overall profitability for the quarter.
Cash and Cash Equivalents	$2 million	Balance as of September 30, 2025.
Corvex Private Placement Financing	$37.1 million	Capital raised by Corvex concurrent with the merger.
Movano Series A Financing	$3.0 million	Equity capital raised by Movano concurrent with the merger.
Loan Repayment Premium	$3.0 million	Contingent cost related to the loan amendment tied to the merger.

The company anticipates the need for further financing to support its operations beyond the first quarter of 2026. Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers for Movano Inc.'s revenue generation as of late 2025. Honestly, the story here is one of transition-moving from initial product sales to building out the more structured, high-value B2B/clinical revenue channels. The current figures reflect that early commercial stage.

The primary recognized revenue stream centers on the Sales of the Evie Ring to the direct-to-consumer market. This is the initial path to market for the consumer-facing wearable, leveraging digital marketing to reach women directly through the company's website. However, the company is clearly positioning for a pivot toward more institutional revenue.

The other key components of the intended revenue mix involve the EvieMED Ring and partnerships. This includes potential B2B licensing or subscription fees for the EvieMED Ring and data platform, which is the FDA-cleared version of the device. Also critical is capturing Pilot study and clinical trial revenue from pharmaceutical and payor partners, which validates the medical utility and provides non-product revenue while the EvieMED is being adopted.

Here's a quick look at the top-line financial performance as reported:

Revenue Metric	Amount
Revenue for the nine months ended September 30, 2025	$0.389 million
Revenue for the quarter ended September 30, 2025	$0.08 million
Revenue in Fiscal Year 2024	$1.01 million
Trailing Twelve Months (TTM) revenue as of December 2025	$0.47 million

The difference between the nine-month figure and the TTM figure suggests the revenue recognized in the final quarter of 2025 (October through December) was relatively small, or the TTM calculation is based on a slightly different period ending in December 2025, which is common in reporting cycles. What this estimate hides is the exact mix of DTC versus any early B2B revenue recognized by year-end.

The overall revenue generation strategy is built on these distinct pillars:

• Direct sales of the consumer Evie Ring via DTC channels.
• Future recurring revenue from B2B subscriptions for the EvieMED platform.
• Project-based revenue from clinical trials with partners.
• Revenue from payor partnerships utilizing the device data.

To be fair, the current revenue base is small, reflecting the focus on regulatory milestones and building inventory for larger B2B contracts. Finance: draft 13-week cash view by Friday.